Literature DB >> 24139385

Intravenous thrombolysis with recombinant tissue plasminogen activator in vascular warning syndromes.

A González Hernández1, O Fabre Pi2, F Cabrera Naranjo2, A C López Veloso2.   

Abstract

INTRODUCTION: Vascular warning syndromes constitute a neurological emergency due to their associated high risk of established stroke. At present, there is no strong evidence indicating the best treatment for these patients. The aim of this paper is to describe the function of intravenous rt-PA thrombolysis in the treatment of vascular warning syndromes.
MATERIAL AND METHODS: We reviewed our hospital records and the literature to find patients with neurologically fluctuating profiles and who underwent intravenous rt-PA thrombolysis.
RESULTS: We retrieved 3 cases from our hospital records and 19 from the literature (15 males and 7 females). Mean age was 68.7±9 years (range: 52-84 years). The mean number of episodes before treatment was 4 (range: 2-15 episodes). The maximum NIHSS scores ranged from 6 to 22 in different patients. We obtained 24-hour post-treatment NIHSS scores in 8 cases; of these cases, 6 (75%) had a score of 0, and the other 2 (25%) had a score of 12. The Modified Rankin Score calculated at 3 months of treatment was 0 or 1 in 18 patients (81.8%); these 18 comprised 8 of the 10 patients with lacunar warning syndromes (80%), 6 of the 7 with basilar warning syndromes (85.7%), and 4 of the 5 with fluctuating non-lacunar, non-basilar warning syndromes (80%).
CONCLUSIONS: Intravenous rt-PA treatment may constitute an effective and safe therapeutic alternative for patients with neurovascular fluctuations. However, well-designed studies are needed to determine the role of intravenous rt-PA thrombolysis in cases of vascular warning syndrome.
Copyright © 2013 Sociedad Española de Neurología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Acute stroke; Basilar warning syndrome; Capsular warning syndrome; Ictus agudo; Ictus isquémico; Ischemic stroke; Síndrome de alarma basilar; Síndrome de alarma capsular; Síndrome de alarma vascular; Thrombolysis; Tratamiento; Treatment; Trombólisis; Vascular warning syndrome

Mesh:

Substances:

Year:  2013        PMID: 24139385     DOI: 10.1016/j.nrl.2013.07.005

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  4 in total

1.  rt-PA with Antithrombotic Therapies in a Case with Capsular Warning Syndrome.

Authors:  Yasuhiro Fuseya; Miyuki Kawamura; Eri Matsuda; Kozue Takada; Kiwamu Watanabe; Junko Fujitake; Yoshifumi Nakaya
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

2.  Intravenous tirofiban therapy for patients with capsular warning syndrome.

Authors:  Wei Li; Ya Wu; Xiao-Shu Li; Cheng-Chun Liu; Shu-Han Huang; Chun-Rong Liang; Huan Wang; Li-Li Zhang; Zhi-Qiang Xu; Yan-Jiang Wang; Meng Zhang
Journal:  Stroke Vasc Neurol       Date:  2019-01-09

3.  Two cases of rt-PA with dual antiplatelet therapies with capsular warning syndrome.

Authors:  Xiaofan Xue; Heng Zhou; Lichun Zhou
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

4.  r-tPA with loading dose of clopidogrel and aspirin therapies for capsular warning syndrome attributed to middle cerebral artery atherosclerotic stenosis: A CARE-compliant case report.

Authors:  Jinghan Xu; Meiting Zhuang; Guanshui Bao; Yu Zhai; Guo-Yuan Yang; Gang Xue; Qiang Li
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.